Old Wegmaster from Yahoo Board
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mystery. Amgen has been silent. Now they are out. Can KB do anything before effective date in Feb?
Benefit of being free agent with HOT? We need a fricking break.
I wonder if Astra Zeneca is looking to improve things with this news:
AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and it has confirmed the study is a failure.
http://www.pmlive.com/pharma_news/azs_mystic_survival_data_is_in_and_its_a_bust_1260766
Merck, they have deep pockets.....
James, Do you think another suitor is standing in the wings? Since Amgen was not making any milestone payments, perhaps we are better off. Amgen was a hope. I pray this is only positive.
Hov, Thank you. Scammy go away with your garbage. Let's stay with facts.
Hov, Would you dare predict a ballpark figure/ range?
Scammy or Short guy or whoever you are...I like this one
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160973/
Overall, multiple clinical trials have demonstrated an excellent safety profile with attenuated Lm vaccines in humans.
One such strategy has been to directly target angiogenesis using Lm vaccines. Indeed, Lm vaccines targeting tumor-associated angiogenic proteins, including CD105 and VEGFR2, have demonstrated inhibited tumor growth [97,98,99,100] as well as the ability to induce secondary antitumor immune responses via epitope spreading [98,99].
....Other studies are likely to explore combination approaches using Lm vaccines with radiation, chemotherapy, immune checkpoint inhibitors, and other drugs. These studies are expected to firmly establish the utility of Lm vaccines in the emerging immunotherapeutic landscape for the benefit of patients with a variety of malignancies.
You are not getting my stock Scammy. Some of us don't need losses or like losses. We are far from over. No fat ladies are even close to humming or even in the neighborhood.
It is a steal. If was not in so big, I would bet bigger.
I did not hear the entire presentation. It seems the tone from Ken is calm. Whether he is faking it, I don't know. Steady as she goes. No milestones being reached in weeks, months, sorry. In the meantime the shorts are feeding on us, as usual. Data-----> Partnership -------> SP?? in the meantime cash has to last until data day. I know Tic Toc on cash. Good Ken is there for spending cuts all and all.
In addition to continuing its AIM2CERV trial for AXAL, the Company plans to initiate an investigator-sponsored trial with a major research center in head and neck cancer in early 2019. The Company is also continuing to follow subjects in its Phase 1/2 study of ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer. Intriguing early data from 37 patients in this study presented at the American Society of Clinical Oncology (ASCO) earlier this year showed an improvement in survival in subjects with PSA declines from baseline of 50% or greater (~19% of all treated subjects). The Company expects to provide an update on survival rates along with correlative biomarker work in the first quarter of 2019.
The Company’s Phase 1 dose-escalation study of ADXS-NEO expressing personalized tumor antigens in subjects with various solid tumors, in collaboration with Amgen, is continuing to enroll subjects and Advaxis anticipates providing safety, tolerability and immune correlative data from the first two cohorts in the first half of 2019.
The Company also continues to progress its ADXS-HOT 503 drug candidate, expressing public (shared) tumor antigens both as monotherapy and in combination with KEYTRUDA® for the treatment of non-small cell lung cancer (NSCLC). The Company plans to have the first subject enrolled in this Phase 1/2 study by the end of 2018 with an anticipated readout of safety, tolerability and immune correlative data from the first cohort in the first half of 2019.
I agree. The time lag is painful, but with no bad clinical news, we get slammed by shorts. Hopefully loss takers and shooters will go away in the next couple of weeks.
All these posts seem like they are from "shooters" not long holders. I am wondering if any significance to 5 pm presentation after market closed. Next data news ?
from 10/18 presentation:
ADXS-HPV (axalimogene filolisbac)
• Announce planned Investigator Sponsored Trial in Head and Neck Cancer
Q4 2018
ADXS-HOT Prostate
• IND Submission
Q4 2018
Looks like about 30% still owned by Tutes.
Lots of good data in there for ADXS. I like this one:
Overall, multiple clinical trials have demonstrated an excellent safety profile with attenuated Lm vaccines in humans.
St Judes does great work. My father was an neonatologist and worked with them. I'll put some winnings their way too.
I bought 55,000 Shares this morning between .45 and .47. I feel good about it. Science wise, we have never had really bad news. Cash and spending has been our issue. Ken now has grip on his budgets and now needs to put his marketing hat on.
There is a lot of money out there from this bull market that make be looking for interest. Lm Tech!!
A Proprietary Antigen Delivery Platform that Activates the Immune System, Naturally
Lm Technology represents an advancement in the field of immunotherapy, as its comprehensive immune stimulation and priming redirects a “pathogen-like” response against cancers. The Lm Technology vector, the basis of each of our products, is designed to stimulate multiple immunotherapy mechanisms. When compared to traditional cancer treatments such as chemotherapies, Lm Technology product candidates are generally well-tolerated, with mild to moderate, transient adverse events. Importantly, Advaxis’ product candidates have the potential for combination with conventional and novel therapies, including other immunotherapy products that modulate the immune response, such as checkpoint inhibitors, co-stimulatory agents, radiation therapy, and other active cancer therapies.
Something is going on. Up big....Registration for securities.
James, you are obviously no dummy, perhaps a gambler, but very smart. Data Data Data, just like Ken said....we patiently wait. I feel good things coming....we have never really had bad data.
I always wonder if restricted holders (ie the board members) can privately buy puts as hedge for their options compensation
That is Better than:
"This is the end, my only friend the end."
All we need is about $100 million from non dilutive source to ride us through the data wave horizon. Biotech takes time and patience and deep pockets.
Somebody knows something and there is A reason, it is not being abandoned which must be positive...hint hint ??
Jckrdu, since we have a race between cash need and data feed (6 months to decision time), how do you see cash actually materializing with your outlined scenarios? Also is not Amgen due for milestone payments?
And within 6 months "DATA, DATA, DATA". Who is willing to bet on this data. Can it save our SP? I pray.
Good Luck to us all. We deserve a break and should not need luck.
The suspense is brutal. Trick or Treat? We are getting beaten down. One positive is we still have some cash.
Amen, I am down major also....I have no where to go. We have have been played by market manipulators. I always wonder if insiders have short positions to cover their restricted stock.
we sit here at a $40M market cap with approximately $50M in cash.......great post. We have to believe we are a bargain buyout at these prices. Will the board accept such...? or beggars can't be choosers?
Upcoming things to look forward to....
Anticipated Milestones Over the Next 12 Months with
TARGET
ADXS-HPV (axalimogene filolisbac) • Announce planned Investigator Sponsored Trial in Head and Neck Cancer Q4 2018
ADXS-HOT Prostate • IND Submission Q4 2018
ADXS-PSA • MetastaticProstatePh1/2Combinationwithpembrolizumab-- Part B Monotherapy Combination Therapy Data (12-mo PFS and OS) Q1 2019
ADXS-NEO • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT NSCLC • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT Bladder • IND Submission 2019
ADXS-HOT Construct #4 • IND Submission
Selected from Breast, ovarian, MSS-CRC, H&N 2019
There is no bad news. Just silence. ADXS is not quite the PR machine. The timelines are farther out than the SP can bear. We need some good news desperately.
Cantor Fitzgerald Global Healthcare Conference- Anyone know anything on this...Were we actually there?
The world is too slow to be smart. You can only hit some folks on the head with a 2 x 4 so many times till some common sense comes in....or never.
and let me guess, these dosage levels are conservative, not even showing potential on less sick patients and higher dosage...
They are big in theatre market.
https://allure-christie.com
Website impressive.
Here is parent company Christie, like 80 years old.
https://www.christiedigital.com/en-us/about-christie/christie-locations
Would they not have to report/ file their trade activity?
Does anyone know who below is?
) CVI Investments, Inc.
(ii) Heights Capital Management, Inc.
Item 2(b).
Address of Principal Business Office or, if none, Residence
The address of the principal business office of CVI Investments, Inc. is:
P.O. Box 309GT
Ugland House
South Church Street
George Town
Grand Cayman
KY1-1104
Cayman Islands
Wow! Talk about manipulation!
January 2018
http://veterinarynews.dvm360.com/aratana-receives-conditional-approval-canine-osteosarcoma-vaccine
In a clinical study of 18 client-owned dogs with osteosarcoma, the data suggest that the vaccine may delay or prevent metastatic disease and may prolong overall survival in these patients. The single-arm study evaluated dogs that had primary tumor removal and four doses of carboplatin chemotherapy, followed by the therapeutic vaccine every three weeks for three doses, according the release. The median survival time was 956 days compared with 423 days for a historical control group (p<0.05).
The most common adverse events included lethargy, diarrhea and fever, according to a separate field safety study that was submitted to the USDA for the conditional licensing process.
To progress from conditional licensure to full licensure as required by the USDA, Aratana plans to conduct an extended field study in a clinical setting, anticipating an early 2018 start to that study, the release notes. Initially, the therapeutic will be available for purchase at about two dozen veterinary oncology practice groups across the United States that participate in the study.
Excellent Post. While the canine is not the potential biggest dollars, it is a excellent PR and very appealing to a broad audience, hence a higher profile While these deals with big pharm may be at conferences ADXS needs to sell sell sell and get a deal. That is the job at hand. Testimonial re: survivors in canine, would get a lot of attention. Things could change quickly with some much needed good news....we are due a break.